Medico Remedies Q2 FY27 Results: What the Numbers So Far Show

Medico Remedies trades near Rs 32.5, down 4.3% recently. 52-week range Rs 30.22 to Rs 56.88. Jun26 revenue Rs 69.4 cr, OPM 4.76%.

Track the latest Medico Remedies Ltd. share price on Univest.

Medico Remedies Q2 results for the September 2026 quarter are the next big checkpoint for the formulations maker, and investors tracking the stock are already lining up expectations around revenue, operating margin and profit for the three months ended September 30, 2026. This preview looks only at what the company has already reported, quarter by quarter, so that the Medico Remedies Q2 results discussion stays grounded in verified numbers rather than guesswork.

Medico Remedies Q2 Results Date

No official date for the Medico Remedies Q2 results has been announced yet. Listed companies in India typically announce September-quarter (Q2 FY27) numbers through October and November, once the board finalises the quarterly financial statements. Until Medico Remedies Ltd. issues a formal exchange intimation, any specific date for the Medico Remedies Q2 results remains unconfirmed, and readers should rely only on the company’s own filings with NSE and BSE for the confirmed schedule.

Medico Remedies Q2 Results Expectations

Medico Remedies Q2 Results Expectations for this cycle are better framed around trend and margin behaviour than any single rupee figure, since Univest does not publish numerical forecasts. The single biggest swing factor going into the Medico Remedies Q2 results is operating margin (OPM), which has been unusually volatile over the last two reported quarters. OPM spiked to 12.59% in Mar26 then fell back to 4.76% in Jun26, a possible one-off that the screener notes could not confirm. Whether that Jun26 OPM level of 4.76% holds, recovers toward the 7 to 8% band seen in Sep25 and Dec25, or drifts further is the central question shaping Medico Remedies Q2 Results Expectations this quarter. Revenue has been on a broadly rising path across the last five quarters, from Rs 38.25 cr in Jun25 to Rs 69.4 cr in Jun26, and whether that top-line momentum continues is a second factor to watch heading into the Medico Remedies Q2 results.

Also read – Dabur India Q2 Results FY27 Preview

Previous Quarter (Q1 FY27, Jun26) Performance

In the immediately preceding quarter, Jun26 (Q1 FY27), Medico Remedies reported revenue of Rs 69.4 crore, operating profit of Rs 3.3 crore, an OPM of 4.76%, and net profit of Rs 2.52 crore. Revenue rose sequentially from Rs 56.81 crore in Mar26, but operating profit and margin fell sharply from the Mar26 print of Rs 7.15 crore and 12.59% OPM. This gap between rising sales and falling operating profitability is the backdrop against which the Medico Remedies Q2 results will be read once reported.

Q2 FY26 (Sep25) Base Quarter

The year-ago comparison base for the Medico Remedies Q2 results is Sep25 (Q2 FY26), when the company posted revenue of Rs 52.64 crore, operating profit of Rs 2.73 crore, OPM of 5.19%, and net profit of Rs 2.57 crore. Any year-on-year reading of the Medico Remedies Q2 results, once announced, will be measured against this Sep25 base of Rs 52.64 crore in revenue and 5.19% OPM.

Recent Trend: Jun25 Through Jun26

Looking at the full run of reported quarters gives useful context for the Medico Remedies Q2 results. Revenue moved from Rs 38.25 cr (Jun25) to Rs 52.64 cr (Sep25) to Rs 58.68 cr (Dec25) to Rs 56.81 cr (Mar26) and Rs 69.4 cr (Jun26), a broadly upward path with one sequential dip in Mar26. Net profit moved from Rs 1.82 cr, Rs 2.57 cr, Rs 2.87 cr, Rs 5.86 cr and Rs 2.52 cr across the same five quarters, meaning the Mar26 profit spike to Rs 5.86 crore has not repeated in the most recent quarter. This five-quarter arc, ending just before the period covered by the Medico Remedies Q2 results, shows revenue growth running ahead of consistent profit growth.

Key Factors to Watch in Medico Remedies Q2 Results

A few themes stand out ahead of the Medico Remedies Q2 results. First, the sustainability of the Jun26 OPM of 4.76% versus the Mar26 spike of 12.59% is unresolved from the data alone. Second, revenue growth has been consistent even as margins swung, so whether that sales momentum keeps building matters as much as the margin line for the Medico Remedies Q2 results. Third, with a return on equity of 19.0% and a debt-to-equity ratio of just 0.25, the balance sheet carries relatively low debt levels into this results season, which is a structural factor rather than a quarter-specific one, and adds context to how the Medico Remedies Q2 results might be received.

Valuation Ahead of Medico Remedies Q2 Results

Also read – Dalmia Bharat Q2 Results FY27 Preview

At a CMP of Rs 32.5, Medico Remedies Ltd. trades at a trailing PE of 19.56 and a price-to-book (PB) of 3.57, against a book value of Rs 9.1 per share and an EPS of Rs 1.66. Return on equity stands at 19.0% and the debt-to-equity ratio is 0.25. The stock carries a market capitalisation of about Rs 270 crore and does not currently pay a dividend (dividend yield 0.0%). These are the valuation markers investors are likely to revisit once the Medico Remedies Q2 results are out and updated trailing earnings are available.

What to Watch in Medico Remedies Q2 Results

Beyond the headline revenue and profit lines, three things are worth watching when the Medico Remedies Q2 results are finally announced. One, whether OPM stabilises closer to the 5 to 7% band seen across most of the last five quarters or reverts toward the Mar26 high. Two, whether the revenue growth trajectory from Rs 38.25 cr to Rs 69.4 cr over five quarters continues into the September 2026 quarter. Three, how the stock’s technical setup, currently below both its 50-day moving average of Rs 41.32 and 200-day moving average of Rs 43.79, with an RSI of 27.22, reacts once the numbers are public. None of this is a forecast of the Medico Remedies Q2 results themselves, only a list of the metrics that historical data suggests are worth tracking.

Investors who want to track Medico Remedies Ltd. and other stocks ahead of results season can open a demat account with Univest here: https://univest.in/open-demat-account.

Conclusion

The Medico Remedies Q2 results for the quarter ended September 2026 have not been announced yet, and this preview has deliberately stuck to verified historical numbers rather than inventing a date or a forecast. Revenue has grown steadily across the last five quarters while operating margin has swung meaningfully, most recently falling to 4.76% in Jun26 from a Mar26 high of 12.59%. That volatility, together with a moderate valuation profile, is the context in which the Medico Remedies Q2 results will be assessed once the company confirms its board meeting date and reports the numbers.

To stay updated the moment Medico Remedies Ltd. announces its results date, set up a free account through Univest: https://univest.in/open-demat-account.

Readers who track pharma and formulations names ahead of the Medico Remedies Q2 results can start a Univest demat account today: https://univest.in/open-demat-account.

This article is prepared for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Historical financial figures are based on publicly available quarterly filings and may be subject to revision; no results date, estimate, or forecast for the upcoming quarter has been stated or implied by Univest. Investments in securities are subject to market risk, and readers should consult a SEBI-registered investment advisor before making any investment decision. Univest Research (SEBI Registration No. INH000013776) is not liable for the accuracy of third-party data referenced above.

When will Medico Remedies Q2 results be announced?

Ans. No official date for the Medico Remedies Q2 results has been announced yet. Companies typically announce September-quarter (Q2 FY27) numbers through October and November, and readers should check NSE or BSE filings for the confirmed date.

What was Medico Remedies revenue and OPM in the previous quarter (Jun26)?

Ans. In Jun26 (Q1 FY27), Medico Remedies reported revenue of Rs 69.4 crore, operating profit of Rs 3.3 crore, an OPM of 4.76%, and net profit of Rs 2.52 crore.

How did Medico Remedies perform in Q2 FY26 (Sep25), the base quarter for comparison?

Ans. In Sep25 (Q2 FY26), the company posted revenue of Rs 52.64 crore, operating profit of Rs 2.73 crore, OPM of 5.19%, and net profit of Rs 2.57 crore.

What is Medico Remedies’ current valuation ahead of Q2 results?

Ans. At a CMP of Rs 32.5, Medico Remedies Ltd. trades at a trailing PE of 19.56 and a price-to-book (PB) of 3.57, with a return on equity of 19.0% and a debt-to-equity ratio of 0.25.